Vemurafenib and cobimetinib overcome resistance to vemurafenib in -mutant ganglioglioma.
作者信息
Touat Mehdi, Gratieux Julie, Condette Auliac Stephanie, Sejean Karine, Aldea Sorin, Savatovsky Julien, Perkins Géraldine, Blons Hélène, Ligon Keith L, Idbaih Ahmed, Hollebecque Antoine, Gimenez-Roqueplo Anne-Paule, Laurent-Puig Pierre, Sanson Marc, Villa Chiara, Di Stefano Anna Luisa
机构信息
From Sorbonne Université (M.T., A.I., M.S., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Department of Oncologic Pathology (M.T., K.L.L.), Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; Department of Neuroradiology (J.G., S.C.A.), Pharmacy Department (K.S.), and Departments of Neurosurgery (S.A.), Pathology (C.V.), and Neurology (A.L.D.S.), Hôpital Foch, Suresnes; Department of Radiology (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Département de Génétique (G.P., A.-P.G.-R., P.L.-P.), and Service de Biochimie, UF de Pharmacogénétique et Oncologie Moléculaire (H.B.), Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris; INSERM (G.P., H.B., P.L.-P.), UMR S 1147, Paris; Drug Development Department (A.H.), Gustave Roussy, Université Paris-Saclay, Villejuif; INSERM (A.-P.G.-R.), UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris; and Université Paris Descartes (H.B., A.-P.G.-R., P.L.-P.), Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
出版信息
Neurology. 2018 Sep 11;91(11):523-525. doi: 10.1212/WNL.0000000000006171. Epub 2018 Aug 17.
Abstract
摘要
相似文献
1
Vemurafenib and cobimetinib overcome resistance to vemurafenib in -mutant ganglioglioma.维莫非尼和考比替尼克服了BRAF V600E突变型神经节胶质瘤对维莫非尼的耐药性。
Neurology. 2018 Sep 11;91(11):523-525. doi: 10.1212/WNL.0000000000006171. Epub 2018 Aug 17.
2
Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.BRAF V600E 突变型低级别神经节胶质瘤中 BRAF 和 MEK 抑制的联合应用。
J Clin Pharm Ther. 2020 Oct;45(5):1172-1174. doi: 10.1111/jcpt.13112. Epub 2020 Jan 27.
3
Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.对不耐用维莫非尼的 BRAF V600E 突变的间变性 ganglioglioma 青少年使用 BRAF/MEK 抑制剂 dabrafenib/trametinib 的反应。
Pediatr Blood Cancer. 2018 May;65(5):e26969. doi: 10.1002/pbc.26969. Epub 2018 Jan 30.
4
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.阿替利珠单抗、维莫非尼和考比替尼作为不可切除的晚期 BRAF 突变阳性黑色素瘤的一线治疗药物（IMspire150）：随机、双盲、安慰剂对照、III 期临床试验的主要分析。
Lancet. 2020 Jun 13;395(10240):1835-1844. doi: 10.1016/S0140-6736(20)30934-X.
5
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.间歇性联合RAF和MEK抑制对一名同时患有BRAF和NRAS突变恶性肿瘤患者的疗效。
Cancer Discov. 2014 May;4(5):538-45. doi: 10.1158/2159-8290.CD-13-1038. Epub 2014 Mar 3.
6
Sustained Tumor Control With MAPK Inhibition in V600-Mutant Adult Glial and Glioneuronal Tumors.MAPK 抑制在 V600 突变型成人神经胶质瘤和神经胶质神经元肿瘤中的持续肿瘤控制。
Neurology. 2021 Aug 17;97(7):e673-e683. doi: 10.1212/WNL.0000000000012330. Epub 2021 Jun 4.
7
Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.评论：一名对维莫非尼不耐受的BRAF V600E突变型间变性节细胞胶质瘤青少年患者对BRAF/MEK抑制剂达拉非尼/曲美替尼的反应
Pediatr Blood Cancer. 2021 Apr;68(4):e28814. doi: 10.1002/pbc.28814. Epub 2020 Nov 19.
8
Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.复发性BRAFV600E突变型神经节胶质瘤对维莫非尼单药治疗的反应
J Transl Med. 2014 Dec 19;12:356. doi: 10.1186/s12967-014-0356-1.
9
Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.联合免疫疗法和靶向治疗治疗 BRAF 突变型晚期黑色素瘤的疗效比较：匹配调整的间接比较。
Immunotherapy. 2019 May;11(7):617-629. doi: 10.2217/imt-2018-0208. Epub 2019 Mar 11.
10
Vemurafenib and cobimetinib in BRAF-mutated melanoma.维莫非尼与考比替尼治疗BRAF突变型黑色素瘤
Lancet Oncol. 2014 Nov;15(12):e535. doi: 10.1016/s1470-2045(14)71023-x. Epub 2014 Oct 10.
引用本文的文献
1
VOPP1::EGFR fusion is associated with NFκB pathway activation in a glioneural tumor with histological features of ganglioglioma.在具有节细胞胶质瘤组织学特征的神经胶质瘤中，VOPP1::表皮生长因子受体（EGFR）融合与核因子κB（NFκB）信号通路激活相关。
Acta Neuropathol Commun. 2025 Apr 16;13(1):76. doi: 10.1186/s40478-025-01994-1.
2
Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients.免疫检查点抑制剂相关的颅神经受累：对136例患者的系统文献综述
J Neurol. 2024 Oct;271(10):6514-6525. doi: 10.1007/s00415-024-12660-2. Epub 2024 Sep 3.
3
The Role of Radiotherapy, Chemotherapy, and Targeted Therapies in Adult Intramedullary Spinal Cord Tumors.放疗、化疗及靶向治疗在成人脊髓髓内肿瘤中的作用
Cancers (Basel). 2024 Aug 6;16(16):2781. doi: 10.3390/cancers16162781.
4
Pembrolizumab-associated myositis with striking extraocular muscle contrast enhancement.帕博利珠单抗相关的肌炎伴显著的眼外肌对比增强。
Acta Neurol Belg. 2024 Oct;124(5):1687-1689. doi: 10.1007/s13760-024-02589-8. Epub 2024 Jun 28.
5
Glioneuronal and Neuronal Tumors of the Central Nervous System.中枢神经系统的胶质神经元肿瘤和神经元肿瘤。
Adv Exp Med Biol. 2023;1405:253-280. doi: 10.1007/978-3-031-23705-8_9.
6
BRAF Mutations in CNS Tumors-Prognostic Markers and Therapeutic Targets.脑肿瘤中的 BRAF 突变——预后标志物和治疗靶点。
CNS Drugs. 2023 Jul;37(7):587-598. doi: 10.1007/s40263-023-01016-5. Epub 2023 Jun 2.
7
Rare Neuronal, Glial and Glioneuronal Tumours in Adults.成人罕见的神经元、神经胶质和神经胶质神经元肿瘤。
Cancers (Basel). 2023 Feb 9;15(4):1120. doi: 10.3390/cancers15041120.
8
Construction and Verification of a Novel Pyroptosis-Related lncRNA Signature Associated with Immune Landscape in Gliomas.一种与胶质瘤免疫格局相关的新型焦亡相关lncRNA特征的构建与验证
J Oncol. 2022 Oct 14;2022:7043431. doi: 10.1155/2022/7043431. eCollection 2022.
9
Dyslipidemia in Children Treated with a BRAF Inhibitor for Low-Grade Gliomas: A New Side Effect?用BRAF抑制剂治疗低级别胶质瘤的儿童中的血脂异常：一种新的副作用？
Cancers (Basel). 2022 May 29;14(11):2693. doi: 10.3390/cancers14112693.
10
Innovating Strategies and Tailored Approaches in Neuro-Oncology.神经肿瘤学中的创新策略与定制方法
Cancers (Basel). 2022 Feb 22;14(5):1124. doi: 10.3390/cancers14051124.
本文引用的文献
1
Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.突变型BRAF上调MCL-1以赋予细胞凋亡抗性，MCL-1拮抗剂和考比替尼可逆转结直肠癌中的这种抗性。
Mol Cancer Ther. 2016 Dec;15(12):3015-3027. doi: 10.1158/1535-7163.MCT-16-0017. Epub 2016 Oct 7.
2
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.获得性BRAF抑制剂耐药性：耐药机制的谱、频率、临床行为及表型关联的多中心荟萃分析
Eur J Cancer. 2015 Dec;51(18):2792-9. doi: 10.1016/j.ejca.2015.08.022. Epub 2015 Nov 19.
3
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.维莫非尼用于治疗伴有BRAF V600突变的多种非黑色素瘤癌症。
N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309.
4
BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.BRAF突变和CDKN2A缺失定义了儿童继发性高级别胶质瘤一个临床上独特的亚组。
J Clin Oncol. 2015 Mar 20;33(9):1015-22. doi: 10.1200/JCO.2014.58.3922. Epub 2015 Feb 9.
5
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.在接受单药BRAF抑制剂治疗后病情进展的BRAFV600突变型黑色素瘤患者中联合使用BRAF抑制剂（达拉非尼）和MEK抑制剂（曲美替尼）。
J Clin Oncol. 2014 Nov 20;32(33):3697-704. doi: 10.1200/JCO.2014.57.3535. Epub 2014 Oct 6.
6
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.BRAF V600 突变型黑色素瘤的联合 BRAF 和 MEK 抑制治疗。
N Engl J Med. 2012 Nov 1;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29.
7
Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.Wnt/β-catenin 信号通路和 AXIN1 调控 BRAFV600E 突变激酶抑制剂诱导的人黑色素瘤细胞凋亡。
Sci Signal. 2012 Jan 10;5(206):ra3. doi: 10.1126/scisignal.2002274.
8
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.对 1320 例神经系统肿瘤的 BRAF V600E 突变分析显示，在多形性黄色星形细胞瘤、神经节胶质瘤和脑外毛细胞星形细胞瘤中突变频率较高。
Acta Neuropathol. 2011 Mar;121(3):397-405. doi: 10.1007/s00401-011-0802-6. Epub 2011 Jan 29.
Zotero 插件